Researchers working on an incurable blood cancer can now use a new lab model that could make testing potential new treatments ...

The UCLA advance opens the door to growing other vascularized organ models, including intestines and colons, providing ...

Nutrition scientists have been working to understand the relationship between type 2 diabetes and genes that express a ...

A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset ...

This article makes a valuable contribution to the field by uncovering a molecular mechanism for miRNA intracellular retention, mediated by the interaction of PCBP2, SYNCRIP, and specific miRNA motifs.

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk ...

The initial investigation of 73 patients with CLL in a discovery cohort revealed a strong association between higher BCL-2 dependence and the presence of favorable genetic biomarkers. Moreover, BCL-2 ...

Antiproliferative and proapoptotic effects were observed in tumour cells but not in fibroblasts or non-malignant tissues. siRNA permutations and diverse overhangs influenced gene silencing efficacy.

When Mary Ann Anderson, MBBS, PhD, FRACP, FRCPA, explains the history of venetoclax, the revolutionary BCL-2 inhibitor that has transformed the management of chronic lymphocytic leukemia (CLL) and ...